Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Type of Radionuclide
6.1 Bismuth (Bi -213)
6.2 Lead (Pb-212)
6.3 Radium (Ra-223)
6.4 Actinium (Ac-225)
6.5 Bismuth (Bi-212)
6.6 Astatine (At-211)
6.7 Terbium (Tb-149)
6.8 Others
Chapter 7 Market Segmentation, By Medical Application
7.1 Endocrine Tumors
7.2 Lymphoma
7.3 Bone Metastasis
7.4 Thyroid
7.5 Ovarian Cancer
7.6 Pancreatic Cancer
7.7 Melanoma
7.8 Glioma
7.9 Others
Chapter 8 Market Segmentation, By Geography
8.1 North America
8.1.1 Introduction
8.1.2 United States
8.1.3 Canada
8.1.4 Mexico
8.1.5 Others
8.2 Europe
8.2.1 Introduction
8.2.2 U.K
8.2.3 Spain
8.2.4 Italy
8.2.5 France
8.2.6 Russia
8.2.7 Others
8.3 Asia-Pacific
8.3.1 Introduction
8.3.2 China
8.3.3 India
8.3.4 Japan
8.3.5 Australia
8.3.6 Others
8.4 South America
8.4.1 Introduction
8.4.2 Brazil
8.4.3 Argentina
8.4.4 Others
8.5 The Middle East & Africa
8.5.1 Introduction
8.5.2 South Africa
8.5.3 Others
Chapter 9 Competitive Landscape
9.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
9.2 Market Share Analysis
9.3 Strategies Adopted By Top Companies
Chapter 10 Company Profiles
10.1. Bayer Healthcare
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiative
10.2. Actinium Pharmaceuticals
10.3. NTP Radioisotopes
10.4. Siemens Healthcare
10.5. Triad Isotopes
10.6. Lantheus Medical Imaging
10.7. IBA Group
10.8. AlphaTau
10.9. Plexus NSD
10.10. Mallinckrodt PLC
10.11. Cardinal Health, Inc.
10.12. GE Healthcare
10.13. Bracco Imaging S.P.A
10.14. Eczacibasi-Monrol Nuclear Products
10.15. Nordion, Inc.
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and Forecast 2018-2024(USD Million)
11.1.1 Market Estimation and Forecast by Type of Radionuclide 2018-2024 (USD Million)
11.1.2 Market Estimation and Forecast by Medical Application 2018-2024 (USD Million)
11.1.3 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
12.2 Analyst Opinion (Market Understanding)
12.3 Investment Opportunities
Chapter 13 Appendix
13.1 List of Tables
13.2 List of Figures
